Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis

Janis E. Blair, Yu Hui H. Chang, Meng Ru Cheng, Laszlo T. Vaszar, Holenarasipur R. Vikram, Robert Orenstein, Shimon Kusne, Stanford Ho, Maria T. Seville, James M. Parish

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

In Arizona, USA, primary pulmonary coccidioidomycosis accounts for 15%-29% of community-acquired pneumonia. To determine the evolution of symptoms and changes in laboratory values for patients with mild to moderate coccidioidomycosis during 2010-2012, we conducted a prospective 24-week study of patients with primary pulmonary coccidioidomycosis. Of the 36 patients, 16 (44%) were men and 33 (92%) were White. Median age was 53 years, and 20 (56%) had received antifungal treatment at baseline. Symptom scores were higher for patients who received treatment than for those who did not. Median times from symptom onset to 50% reduction and to complete resolution for patients in treatment and nontreatment groups were 9.9 and 9.1 weeks, and 18.7 and 17.8 weeks, respectively. Median times to full return to work were 8.4 and 5.7 weeks, respectively. One patient who received treatment experienced disseminated infection. For otherwise healthy adults with acute coccidioidomycosis, convalescence was prolonged, regardless of whether they received antifungal treatment.

Original languageEnglish (US)
Pages (from-to)983-990
Number of pages8
JournalEmerging infectious diseases
Volume20
Issue number6
DOIs
StatePublished - Jun 2014

ASJC Scopus subject areas

  • Epidemiology
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis'. Together they form a unique fingerprint.

  • Cite this

    Blair, J. E., Chang, Y. H. H., Cheng, M. R., Vaszar, L. T., Vikram, H. R., Orenstein, R., Kusne, S., Ho, S., Seville, M. T., & Parish, J. M. (2014). Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis. Emerging infectious diseases, 20(6), 983-990. https://doi.org/10.3201/eid2006.131842